Cumulative incidence of adverse events (clinical or laboratory) attributed to the study therapy in the preceding FATT-1 randomized trial (CX401 or fibrin glue) 6 months (since last visit in FATT-1 trial) [clinicaltrials_resource:2f151a100438e53d1867f7c6116eb522]
Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Cumulative incidence of adverse events (clinical or laboratory) attributed to the study therapy in the preceding FATT-1 randomized trial (CX401 or fibrin glue) 6 months (since last visit in FATT-1 trial) [clinicaltrials_resource:2f151a100438e53d1867f7c6116eb522]
Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
Bio2RDF identifier
2f151a100438e53d1867f7c6116eb522
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2f151a100438e53d1867f7c6116eb522
measure [clinicaltrials_vocabulary:measure]
Cumulative incidence of advers ...... d trial (CX401 or fibrin glue)
time frame [clinicaltrials_vocabulary:time-frame]
6 months (since last visit in FATT-1 trial)
description
Patients randomized to experim ...... s.gov identifier: NTC00475410]
identifier
clinicaltrials_resource:2f151a100438e53d1867f7c6116eb522
title
Cumulative incidence of advers ...... ce last visit in FATT-1 trial)
@en
type
label
Cumulative incidence of advers ...... 51a100438e53d1867f7c6116eb522]
@en